Form 4: Sarepta Therapeutics Director Hans Wigzell Reports Stock and Options Transactions

Director Hans Wigzell reports acquisition of Sarepta Therapeutics stock and stock options.

Summary

• On March 10, 2025, Hans Wigzell, a director of Sarepta Therapeutics, reported transactions involving the company's securities.
• Wigzell acquired 2,383 shares of common stock and disposed of 25,223 shares.
• Following these transactions, Wigzell beneficially owns 25,223 shares of common stock.
• Wigzell also acquired 4,792 stock options with an exercise price of $99.69, exercisable from March 10, 2026, to March 10, 2035.
• These stock options are for 4,792 shares of common stock.
• Wigzell was also granted restricted stock units (RSUs), each representing the right to receive one share of common stock, vesting in full on March 10, 2026.
• Following the transaction, Wigzell directly owns 4,792 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports transactions without expressing an opinion on the company's prospects. The sale of shares is balanced by the acquisition of options.

Positives

• The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 25,223 shares by the director could be interpreted negatively by investors.

Risks

• The disposal of a large number of shares by a director could create uncertainty among investors.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.

Key Dates